在全身性红斑狼中使用贝利马布皮质类固醇缓解治疗:现实生活观察研究 (BESST研究)
Marie Jaïs1, Pascal Roblot1,2, François Maillot3,4
1Department of Internal Medicine, Poitiers University Hospital, 2 Rue de La Milétrie, 86021, Poitiers Cedex, France.
Rheumatology international
|April 30, 2024
概括
贝利马布在现实环境中有效地减少了系统性红斑狼 (SLE) 患者的皮质类固醇使用. 这项研究显示,在24个月内,显著且持续的皮质类固醇节约作用.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床药理学 临床药理学
背景情况:
- 有限的现实世界数据存在于贝利穆马布在全身性红斑狼 (SLE) 中的皮质类固醇节约作用.
- 皮质类固醇是SLE管理的基石,但与显著的副作用有关.
- 评估贝利穆马布在减少皮质类固醇依赖方面的作用对于改善患者的治疗结果至关重要.
研究的目的:
- 在现实生活条件下评估贝利穆马布在SLE患者的皮质类固醇节约效果.
- 为了确定患者中达到低剂量或非常低剂量的普得尼松或完全停止普得尼松的比例.
主要方法:
- 在30名SLE患者的多中心观测后期研究中,他们接受了贝利穆马布治疗6个月以上 (2011-2020年).
- 主要终点:在6个月后减少每日普得尼松剂量.
- 二级终点:低剂量 (≤7.5毫克/天),非常低剂量 (≤5毫克/天) 的变化,以及没有普得尼松的状态.
主要成果:
- 在6个月 (10毫克至6.75毫克,p<0.0001) 观察到显著的普得尼松剂量减少,持续至24个月.
- 越来越多的患者在治疗期间获得了非常低的剂量或没有普得尼松.
- 贝利马布的引入与早期和持续的皮质类固醇减少有关.
结论:
- 贝利马布在现实世界SLE管理中表现出显著和持续的皮质类固醇节约作用.
- 这支持贝利马布作为一种有价值的选择,可以降低SLE患者的葡萄糖皮质醇负担.
- 进一步的研究应该探索长期的结果和反应的预测因素.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160